Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...